Viewing Study NCT04636268


Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2025-12-27 @ 8:19 PM
Study NCT ID: NCT04636268
Status: WITHDRAWN
Last Update Posted: 2023-10-23
First Post: 2020-03-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
Sponsor: Instituto Grifols, S.A.
Organization:

Study Overview

Official Title: A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
Status: WITHDRAWN
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: The study was stopped due to a business decision.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia.

This clinical trial is planned to be performed at study sites in multiple countries. It is planned to include a maximum of 32 adult and pediatric subjects with congenital fibrinogen deficiency in order to provide at least 28 evaluable acute bleeding episodes and/or surgical procedures.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2018-004005-81 EUDRACT_NUMBER None View